



Received on 09 September 2023; received in revised form, 15 November 2023; accepted 12 December 2023; published 25 December 2023

OMICRON: THE VARIANT OF CONCERN

Mrs. Preeti Mishra¹, Deeksha Tiwari¹, Dilip Kumar Chanchal² and Vivek Pal^{*2}

Faculty of Pharmacy¹, Raja Balwant Singh Engineering Technical Campus Bichpuri, Agra - 283105, Uttar Pradesh, India.

Department of Pharmacy², Smt. Vidyawati College of Pharmacy, Jhansi - 284128, Uttar Pradesh, India.

ABSTRACT

Background: OMICRON, a SARS-COV-2 strain, has generated global concern. This brief article discusses the discovery and dissemination of, which spurred hypotheses about omicron's genesis and infectious responsibility. Mutant strain in spike protein's RBD region exceeds vaccine immunity, causing worry. The next part discusses transmission, infectivity, morbidity, and COVID-19 immunisation. Classification: WHO and TAG-VE suggested viral evolution on November 26, 2021. They called B.1.1.529 omicron. This finding was based on TAG-VE data showing that Omicron has various alterations that affect how it acts, such as how easy it spreads or the severity of the disease it caused. Symptoms: The unique COVID variation "Omicron" caused high fever, sputum, fatigue, and loss of taste and smell. Transmission: How Omicron was more transmissible than Delta is unclear. In Africa, where this variation is prevalent, more persons are positive. Epidemiological research will identify whether this is related to Omicron or other variables. Severity: Due to improved population immunity and lower severity of intrinsic Omicron infections, the Omicron outbreak will likely have a lower impact on people's health than prior covid-19 waves. In South Africa's predominantly youthful population, 21% were hospitalised with SARS-CoV-2 Omicron. Patients with catastrophic clinical outcomes might rise during epidemics in communities with numerous enumerations and lower disease levels or give vaccination protection. Milder symptoms in South Africa following omicron versus delta infection are comforting. Omicron strain breakouts won't have little health effects elsewhere. Treatment: Remdesivir, Molnupiravir, and Paxlovid (not yet available in India) are suggested in the early stages of a viral infection. This prevents the illness from developing. Conclusion: Most therapeutic antibodies licenced to treat covid-19 are ineffective in the Omicron variant, according to the research.

Keywords: Omicron, Covid-19, Treatment, Variants.

Correspondence to Author: Vivek Pal, Department of Pharmacy, Smt. Vidyawati College of Pharmacy, Jhansi - 284128, Uttar Pradesh, India. Email: vpal6835@gmail.com

INTRODUCTION

A new variation of covid-19 named as Omicron (the Greek alphabet 15th letter) was found in November 2021. World Health Organization used Greek letters to represent strains because they are uncomplicated in comparison to scientific attribute like B.1.617.2. According to the WHO, since "nu" feature "new" and "xi" is feature common surname omitted the 13th and 14th Greek letters (nu and xi). The article in Nature on November 25, 2021 by Ewen Calloway headlined "Heavily altered sparked curiosity

concerning the OMICRON variant. on November 26, 2021, The B.1.1.529 strain on SARS-CoV-2 Virus Evolution (TAG-VE) is invented in South Africa as OMICRON undergoing the Variants of Concern (VOC) category was named by the WHO's Technical Advisory Group¹.

Under a week of its discovery, the Omicron obtained worldwide attention and became a global impact. Such as a result, Brief note includes Omicron's recent state, its variations in the spike protein and their ramifications,

immuization efficacy, and COVID-19 preventative and travel-related cautions².

Omicron's Classification (B.1.1.529):

RNA viruses have the ability to replicate (mutation) and change in order to adjust and persist in varying environments. More than 50 mutations in the OMICRON variation, of which around 30 transformations are in the end protein, are a very worrying feature. before cell entrance, human cells potentially increasing transmissibility are interacted by the 15 changed locations in the receptor-binding domain (RBD), which are the most concerning³.

An independent group of experts is TAG-VE (Technical Advisory Organization on SARS-CoV-2 Virus Evolution) determines and analyzes SARS-CoV-2's development on a regular basis, confining whether certain mutations or varieties of modifications convert the viral behavior. The SARS-CoV-2 variant B.1.1.529 is analyzed by the TAG-VE On November 26, 2021⁴.

South Africa had firstly notified the B.1.1.529 variant to WHO On November 24, 2021. In reported cases, three different peaks have marked the epidemiological situation in South Africa, the numerous current of which was overwhelmed through the Delta strain. In current weeks, Illnesses have grown dashing, harmonizing with the finding of the B.1.1.529 variant⁵. On November 9, 2021, A sample was collected, firstly reported and verified as B.1.1.529 infection⁶.

This variation has numerous transformations of which some cause many problems. In respect to other VOCs, primary investigation suggests that higher risk of reinfection caused by this variation⁷. In virtually all of the regions of South Africa, the numeral of cases increases with this variation. current SARS-CoV-2 PCR diagnostics detect this strain. Many laboratories had informed that in one widely used PCR test (learned as S gene withdraw or

S gene target loss) does not find one of the three target genes. As a marker, a PCR test can be used for sequencing confirmation of this variant. using this method. This variation can be found at more rapid rates than previous episodes, suggesting that this test have numerous advantage⁸.

A miscellany of examinations undergoes, and this variant will be continued to assess by the TAG-VE. As warranted, additional findings with the Member States and the general public will be shared by WHO⁹.

The TAG-VE has informed WHO that VOC as a variant shall declare and B.1.1.529 as a VOC has been identified by the WHO, named Omicron, founded on the report provided and exhibiting a deleterious change in COVID-19 world widely¹⁰.

As a result, countries are urged to take the following steps:

- For pleasingly understanding distributing mutation of SARS-CoV-2, increase monitoring and sequencing activities.
- Whole-genome arrangements and accompanying information should be submitted to socially accessible information in a form of GISAID.
- Through the IHR process should be a message startlingly patients/groups of VOC infection to WHO.
- By Performing field examinations and laboratory examinations are carried to improve knowledge of the possible results of the VOC on COVID-19 world widely, harshness, the efficacy of social fitness and social standards, diagnostic procedures, resistant responses, antibody-antibody reaction, or other appropriate features, where ability lives and in work with the global community¹¹.

Proven public fitness and social techniques should be used by People to reduce their chance of COVID-19, such as sporting well-suitable covers, hand sanitation, social

distance, improving internal aeration bypassing congested areas, and being immunized¹².

For the SARS-CoV-2 variant of Interest (VOI) and Variant of Concern (VOC) for your convenience (VOC), working definitions are offered by WHO¹³.

A SARS-CoV-2 VOI is a variation of SARS-CoV-2:

That has been identified as causing significant community transmission or multiple COVID-19 clusters, in multiple countries, with increasing relative prevalence alongside an increasing number of cases over time, or other apparent epidemiological impacts that suggest an emerging risk to global public health¹⁴.

A SARS-CoV-2 VOC is considered to be a strain of SARS-CoV-2 that, after being subjected to a comparative analysis, is found to have one or more additional mutations at the level of the global public health system. The requirements for a VOI were previously outlined and may be found above¹⁵.

Significance:

- Increased global transmission of COVID-19;
- Increased virulence of COVID-19;
- Change in the clinical presentation of COVID-19;
- Decreased effectiveness of general fitness and colonial features of diagnostics, vaccination, and treatments¹⁶.

Symptoms of omicron variant

Many nations have reintroduced or tightened restrictions in an attempt to curb the spread of the Omicron version of Covid-19¹⁷.

While preliminary research suggests that Omicron is less severe than prior Covid forms, it is thought to be more transmissible and

capable of evading current vaccine protection¹⁸.

The major symptoms of Covid-19, according to the National Health Service in the United Kingdom, are a high temperature, a new and persistent cough, and alterations in people's perception of smell or taste¹⁹.

However, early signals suggest that additional symptoms, including as sneezing, weariness, a headache, lower back discomfort, fever, scratchy throat, night sweats, and a runny nose, are more unique to the Omicron version²⁰.

TRANSMISSION

The major symptoms of COVID-19, according to the National Health Services in the UNITED KINGDOM, are a high temperature, cough and alteration in people's perception of smell or taste²¹.

However, early signals suggest that additional symptoms, including as sneezing, weariness, a headache, lower back discomfort, fever, scratchy throat, night sweats and a runny nose are more unique to the OMICRON version²².

Although it is possible that the OMICRON SARS-COV-2 virus would spread more quickly than the genuine SARS-COV-2 virus, how much faster the OMICRON virus will spread in contrast to the Delta virus is unknown. The Centers for Disease Control and Prevention (CDC) said that everyone with omicron was likely to spread the virus to many others, even if they were vaccinated or showed no symptoms²³.

Community Transmission Of Omicron In India

According to the Indian SARS-COV-2 Genomics Consortium (INSACOG), in india omicron was recently in transmitted in community and had became dominant in

various metros cities, where everyday new cases had been increasing rapidly²⁴.

INSACOG is a collaboration of 38 labs, established to monitor genomic modification in the SARS-COV-2 virus by the Union Ministry of Health and Family Welfare and the Department of Biotechnology (DBT), among others²⁵.

Most omicron instances to far have been asymptomatic or mild, but there has been an increase in hospitalizations and intensive care unit patients in the last wave, as reported in a two-page notice published the previous Sunday. The danger level was still the same²⁶.

It noted that recently reported novel SARS-COV-2 variant – B.1.640.2 – lineage was followed and that, while it exhibited unaffected traits, it was not yet a variety of task. The bulletin stated, “ until now, any case has not been discovered in India²⁷.

It went on to say that BA.2 lineage made up a significant portion of the population in India, and gene-S withdraw-based on screening was to be expected to result in a large number of wrong negatives. The use of test PCR suitable for screening of all Omicron strain had been approved. S-gene drop out, like Omicron, was a genetic variant²⁸.

Meanwhile, the INSACOG cautioned in a report dated January 3 that Omicron had entered and spread in community in India and had grown prevalent in Mumbai and Delhi, where every day new cases had been increasing at higher rate. It went on to note that INSACOG is working on a redesigned sample and sequencing technique to fulfil genomic monitoring goals in light of the fast evolving viral scenario, and that Omicron was predicted to dominate in India via internal transmission rather than through international travellers²⁹.

"So far, the majority of Omicron instances have been asymptomatic or moderate. Because Omicron infection was first detected in vaccinated travellers, this does not guarantee that infection will be minimal in high-risk unvaccinated people. As the situation rapidly evolves with community expansion, the threat level remains high," it had added, adding that COVID-19 proper behaviour and immunisation were the key shields against all form mutations of the SARS-CoV-2 virus³⁰.

SEVERITY OF DISEASE

Whether an Omicron infection is more dangerous than a Delta infection is unknown. Preliminary data suggest that hospitalisation rates are on the rise in South Africa, however this may be attributable to an overall increase in infection rather than any one particular Omicron sickness. So yet, there is no proof that Omicron-specific symptoms are any different from those seen with other variants. It may take a few days to a few weeks to determine the severity of the Omicron variant, although the first instances were found among younger college students. Even the most prevalent COVID-19 variant in the world, Delta, may cause severe illness or death. The best course of action is prevention, particularly as all COVID-19 variants, including the prevalent Delta variant, may cause serious illness or death, especially in the most susceptible individuals³¹.

DEATH RATE OF OMICRON

New COVID-19 cases have surpassed 70,000, and the Union government has described this as a "exponential rise," with the acceleration being "steeper than ever" as shown by a higher R naught value than during the peak of the brutal second wave. The first death associated with the Omicron coronavirus variant was reported in Rajasthan on January 5. Tamil Nadu and Himachal Pradesh have joined a growing list of states to impose night curfews in line with new curbs to deal with the

expanding pandemic, and the Union government has stated that the uptick in COVID cases (a 6.3-fold increase in the last eight days) is occurring in urban areas and that the Omicron variant is the predominant circulating strain³².

There were 653 instances of Omicron in Maharashtra, 464 in Delhi, 185 in Kerala, 174 in Rajasthan, 154 in Gujarat, 121 in Gujarat, and 121 in Gujarat. According to the Union Health Ministry, the Omicron variant was detected in samples taken from the body of a 73-year-old man who passed away last week in Udaipur, Rajasthan³³.

"The victim had already gone dead by the time the Omicron positive findings came in. An older guy with diabetes and other co-morbid ailments, he was receiving standard treatment for both the infection and his other problems. According to our criteria, a death in a coronavirus-positive patient is considered a COVID-19 fatality. Also, if someone is found to be Omicron positive, we will only consider them to be Omicron positive, regardless of when the positivity was discovered." So says Agarwal³⁴.

According to state government authorities, the person died on December 31st at an Udaipur hospital after being revealed to be infected with Omicron during genome sequencing despite having tested negative for the ailment in the past. As more medical professionals have tested positive for COVID in many regions, worries of a catastrophic lack of medical personnel have grown³⁵.

About 160 resident physicians working at Maharashtra government and local municipal corporation hospitals in Mumbai have tested positive for coronavirus in the past three days, according to a senior office-bearer of their union³⁶.

The number of new coronavirus infections in India reached 3,50,18,358 in a single day, the

highest daily total in over 199 days, with the number of active cases reaching 2 lakh after 81 days. There were a total of 58,419 confirmed cases of sickness on June 20 of last year³⁷.

It is estimated that the nationwide COVID total has crossed the 70,000 mark if the evening data provided by certain state agencies is added. There was a dramatic surge in cases in many states in only one day, including Maharashtra, West Bengal, Karnataka, and Delhi³⁸.

It has been reported that COVID instances are rising in urban areas, and the Director General of the Indian Council of Medical Research (ICMR), Dr. Balram Bhargava, has said that "the Omicron variety is the common circulating strain."³⁹

He told a press conference that mass meetings should be avoided to slow the spread of infection, citing the impending Assembly elections in five states, which are expected to see campaign rallies⁴⁰.

Dr. Paul further said that they believe Omicron is largely responsible for the exponential increase of COVID-19 cases. We have more information on this in bigger cities and the western part of our country⁴⁰.

Case positivity rates have increased from 1.1% on December 30 to 1.3% on December 31, and now to 5% on January 5, he said, noting that there were 13,000 COVID cases on December 30, and 58,000 on Tuesday. But he stressed that hospitalisation numbers are low. It's around 3.7 percent in Delhi, and about 5 percent in Mumbai. That's the very first bit of data we have. In contrast, Paul said, the rate of hospitalisation was over 20% in 2018 and will be about 20% in 2020⁴⁰.

He stated that while there is no reason to panic, people must remain vigilant, disciplined, and prepared, adding that the country will also be affected by this phase of

the pandemic. In response to the question of whether India is experiencing a third COVID-19 wave, Paul stated that in other nations, a rapid spike in the number of cases was accompanied by a steep fall in the number of cases⁴⁰.

"Within a month or month and a half, instances in Denmark, the United Kingdom, and South Africa began to decline. For our demographic, we are unable to state this clearly. Past infections, immunisation history, and our personal traits and population density will all influence how it behaves. It cannot be assumed that, exactly as the instances behaved there within a month, the same will occur here," he stated⁴⁰.

According to Lav Agarwal, there has been an increase in the number of COVID cases worldwide, with 25.2 lakh cases reported worldwide on January 4th, "the highest ever since the pandemic began." "In the last eight days, India has reported a 6.3-fold increase in the number of cases, as well as a substantial increase in the case positivity rate, which has risen from 0.79 percent on December 29 to 5.03 percent on January 5," he stated⁴⁰.

Maharashtra, West Bengal, Kerala, Delhi, Karnataka, and Tamil Nadu, according to Agarwal, each have over 10,000 ongoing COVID-19 cases. Maharashtra, West Bengal, Delhi, Kerala, Tamil Nadu, Karnataka, Jharkhand, and Gujarat are also emerging as states of concern, according to him⁴⁰.

Globally death rate of omicron

The first fatality in Israel attributable to the omicron strain of the coronavirus was reported on Tuesday by the country's health ministry. Soroka Hospital in Beersheba reported on Monday that a man in his 60s who had been hospitalised two weeks before had passed away. The document just said that the guy had a history of health issues, however⁴¹.

Meanwhile, CNN reports that a nationwide rollout of a fourth dosage of the coronavirus vaccination is imminent. According to the prime minister's office, the extra dosage would be given to adults over the age of 60, medical staff, and people with impaired immune systems based on a recommendation by the country's panel of coronavirus specialists. The article states that the five-month interval between dosages two and three is now three months⁴¹.

According to Guardian, ECDC head Dr. Andrea Ammon stated, "We estimate the potential of future transmission of the Omicron form throughout the EU/European economic area as extremely high, and it is deemed highly likely to cause more hospitalizations and deaths."⁴¹

United Kingdom of Great Britain

On Monday, Dominic Raab, Britain's deputy prime minister, said that 12 persons infected with the Omicron coronavirus had died in the nation. He also refused to rule out the possibility of more restrictions being implemented before Christmas. The fast spread of the Omicron species before to Christmas has left British authorities in a bind, despite Prime Minister Boris Johnson's denial that a lockdown is likely before the holiday⁴².

United States of America

Health officials have confirmed that a person in Texas died on Tuesday from the new coronavirus Omicron type. Harris County Public Health claims that a man in his 50s from Texas was not vaccinated despite having been exposed to COVID-19⁴³.

According to CNN's reporting, this is the first case of a fatality linked to Omicron in the United States. The person "was at a heightened risk of significant COVID-19 outcomes due to his unvaccinated status and underlying health concerns," the notification

said. The individual, whose age was given as 50 by County Judge Lina Hidalgo, was pronounced dead on Monday⁴³.

TREATMENT

In early 2021, the COVID-19 National Task Force of the All India Institute of Medical Sciences and the Indian Council of Medical Research (ICMR) and the Union health ministry decided to discontinue the treatment⁴⁴.

"The demand of patients affected much of the treatment, especially during the second wave. The use of convalescent plasma therapy, ivermectin, and other similar treatments has increased significantly. "Clinical protocol and perceived advantage should dictate our approach, not a patient's demand," Lahariya stated⁴⁴.

Over the last two years, COVID-19 treatment has gotten much more straightforward. Given a history of previous illness, immunisation, and the fact that omicron likely produces milder infection than its predecessor, the majority of current patients can be managed in home isolation⁴⁴.

In the early stages of a viral infection, antivirals such as Remdesivir, Molnupiravir, and Paxlovid — which is not yet available in India — are indicated. This is generally done to prevent the disease from progressing further⁴⁴.

"Both Remdesivir and Molnupiravir work in a similar way, causing viral mistakes to stop the virus from replicating and raising the viral burden," Rangappa added⁴⁴.

Molnupiravir, on the other hand, has been advised against by experts. While the Drugs Controller General of India has cleared it for usage, the ICMR has decided not to include it in its national COVID-19 treatment protocol due to safety concerns⁴⁴.

"The clinical trials for molnupiravir were conducted in an uninfected group, the majority of whom had never been infected before." This is no longer true for today's Indian population, where the advantages are unknown and the risk of negative effects is significant. Excessive use based on desire and prescription poses a serious risk in India, according to Lahariya⁴⁴.

Despite the ICMR's warnings concerning Molnupiravir's side effects, such as mutagenicity, muscle and bone damage, and the requirement for three months of contraception for women because it may impact the kid, reports show that demand has increased⁴⁴.

CONCLUSION

It seems that omicron has a high rate of transmission. Preliminary analyses by Discovery indicate a correlation between having had the delta version and a 73% increased risk of reinfection with omicron in 2020 first wave afflicted individuals.

The entire extent of the harm caused by omicron-contaminated Covid has yet to be known, but a surge in new cases has the potential to overwhelm healthcare facilities. Shortages of staff may occur in healthcare facilities if the number of affected workers increases and they are forced to stay home and isolate. Furthermore, British geneticist Jeffrey Barrett of the Wellcome Sanger Institute tweeted, "Testing capacity will almost likely fail to keep up with #Omicron: even with utmost efforts, supply can rise linearly, but demand will grow exponentially." This will occur (almost) everywhere at once, endangering the distribution of chemicals, polymers, and other products throughout the world.

Since the omicron strain seems to be evading antibodies, it may be resorting to T-cells, a kind of white blood cell that may prevent a

moderate infection from developing into a major illness. According to US vaccinologist Phil Krause, head of the World Health Organization's Vaccinations Research Expert Group, this barrier of T-cells, both those created by vaccines and those emerging from prior infections, "remains substantially intact against variants including omicron."

REFERENCES

- [1]. RayatiDamavandi A, Dowran R, Al Sharif S, Kashanchi F, Jafari R. Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. *Medical Microbiology and Immunology*. 2022 Mar 2;1-25.
- [2]. Maison DP, Ching LL, Cleveland SB, Tseng AC, Nakano E, Shikuma CM, Nerurkar VR. Dynamic SARS-CoV-2 emergence algorithm for rationally-designed logical next-generation vaccines. *Communications biology*. 2022 Oct 10;5(1):1-2.
- [3]. Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. *Signal Transduction and Targeted Therapy*. 2022 Jun 28;7(1):1-25.
- [4]. Quarleri J, Galvan V, Delpino M. Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. *GeroScience*. 2021 Dec 18:1-4.
- [5]. Patel M, Mazumder R, Kaushik KK, Debnath A, Mishra R, Pal S. A brief description of COVID-19 pulmonary viral infection and repurposing of drugs for its treatment. *International Journal of Applied Pharmaceutics*. 2022 Sep:22-31.
- [6]. Al-Tawfiq JA, Hoang VT, Le Bui N, Chu DT, Memish ZA. The emergence of the omicron (B. 1.1. 529) SARS-CoV-2 variant: what is the impact on the continued pandemic?. *Journal of Epidemiology and Global Health*. 2022 Jan 28:1-4.
- [7]. Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B. 1.1. 529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. *Biomedicine & Pharmacotherapy*. 2022 Aug 15:113522.
- [8]. Lee MC. Factors influencing the adoption of internet banking: An integration of TAM and TPB with perceived risk and perceived benefit. *Electronic commerce research and applications*. 2009 May 1;8(3):130-41.
- [9]. Aker JC, Mbiti IM. Mobile phones and economic development in Africa. *Journal of economic Perspectives*. 2010 Sep;24(3):207-32.
- [10]. Abusalah MA, Khalifa M, Al-Hatamleh MA, Jarrar MT, Mohamud R, Chan YY. Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. *Journal of personalized medicine*. 2022 Mar 3;12(3):386.
- [11]. Ma Y, Rong Y. Design Standards and Regulations. In *Senior Design Projects in Mechanical Engineering 2022* (pp. 361-420). Springer, Cham.
- [12]. Kheifetz Y, Kirsten H, Scholz M. On the Parametrization of Epidemiologic Models—Lessons from Modelling COVID-19 Epidemic. *Viruses*. 2022 Jul 2;14(7):1468.
- [13]. Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, Samant RM, Anderson DJ, Metti J, Khullar G, Baits R. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals. *medRxiv*. 2021 Jan 1.
- [14]. Resende PC, Gräf T, Paixão AC, Appolinario L, Lopes RS, Mendonça AC, da Rocha AS, Motta FC, Neto LG, Khouri R, de Oliveira CI. A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B. 1.1. 33 circulating in Brazil. *Viruses*. 2021 Apr 21;13(5):724.
- [15]. Messali S, Bertelli A, Campisi G, Zani A, Ciccozzi M, Caruso A, Caccuri F. A cluster of the new SARS-CoV-2 B. 1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine. *Journal of Medical Virology*. 2021 Dec 1.
- [16]. Unemo M, Seifert HS, Hook EW, Hawkes S, Ndowa F, Dillon JA. Gonorrhoea. *Nature Reviews Disease Primers*. 2019 Nov 21;5(1):1-23.
- [17]. Khandia R, Singhal S, Alqahtani T, Kamal MA, Nahed A, Nainu F, Desingu PA, Dhama K. Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. *Environmental Research*. 2022 Jun 1;209:112816.
- [18]. Callaway E, Ledford H. How bad is Omicron? What scientists know so far. *Nature*. 2021 Dec 2;600(7888):197-9.
- [19]. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, Boscolo-Rizzo P. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. *Jama*. 2020 May 26;323(20):2089-90.
- [20]. Farrar J, Ahuja A. Spike: The virus vs. the people—the inside story. *Profile Books*; 2021 Jul 22.
- [21]. Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, Bressler JM, Bye E, Crawford R, Morano LH, Lewis NM. Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020. *Morbidity and Mortality Weekly Report*. 2020 Jul 7;69(28):904.
- [22]. Hong B, Kim M. Understanding SARS-CoV-2 Variants and Safety Countermeasures for the Fight against Omicron. *International Journal of Crisis & Safety*. 2022 Mar 30;7:1-2.
- [23]. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA. 1 to BA. 5: Implications for immune escape and transmission. *Reviews in Medical Virology*. 2022 Sep;32(5):e2381.
- [24]. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IA, Datir R, Collier DA, Albecka A, Singh S, Pandey R. CoV-2 Genomics Consortium (INSACOG). Genotype to Phenotype Japan (G2P-Japan) Consortium. 2021:114-9.

- [25]. Indian SA. CoV-2 Genomics Consortium (INSACOG). Genotype to Phenotype Japan (G2P-Japan) Consortium. 2021.
- [26]. Murray CJ. COVID-19 will continue but the end of the pandemic is near. *The Lancet*. 2022 Jan 29;399(10323):417-9.
- [27]. Arora P, Kempf A, Nehlmeier I, Graichen L, Schulz S, Cossmann A, Dopfer-Jablonka A, Winkler MS, Jäck HM, Behrens G, Pöhlmann S. Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B. 1.640. 2. Cellular & Molecular Immunology. 2022 May 17:1-3.
- [28]. Desingu PA, Nagarajan K. Omicron BA. 2 lineage spreads in clusters and is concentrated in Denmark. *Journal of medical virology*. 2022 Jun;94(6):2360-4.
- [29]. Callaway E. Are COVID surges becoming more predictable. *Nature*. 2022 May 12;605.
- [30]. Shervani Z, Bhardwaj D, Hasan S, Qazi UY, Purang M, Ibrahim A, Vuyuru VP, Siddique A, Sherwani A, Khan AA, Fatma K. The Omicron Wave in India, Mumbai, and Delhi: Prevalence and Pathogenicity. *European Journal of Medical and Health Sciences*. 2022 Jun 22;4(3):123-30.
- [31]. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—a systematic review, meta-analysis, and meta-regression. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2020 Jul 1;14(4):395-403.
- [32]. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, Ramlall R, Spoor S, de Villiers T, Van der Walt Z, Cloete J. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. *International Journal of Infectious Diseases*. 2022 Mar 1;116:38-42.
- [33]. Johnson AG. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence—25 US Jurisdictions, April 4–December 25, 2021. *MMWR. Morbidity and mortality weekly report*. 2022;71.
- [34]. Huang J, Zeng G. Epidemiology of the SARS-CoV-2 variant Omicron BA. 2—vigilance needed. *Eurosurveillance*. 2022 Mar 31;27(13):22-00254.
- [35]. Duong BV, Larpruenrudee P, Fang T, Hossain SI, Saha SC, Gu Y, Islam MS. Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?. *International Journal of Environmental Research and Public Health*. 2022 Apr 11;19(8):4586.
- [36]. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. *Jama*. 2022 Feb 8;327(6):583-4.
- [37]. Taylor L. Covid-19: Hong Kong reports world's highest death rate as zero covid strategy fails. *BMJ*. 2022 Mar 17;376(o420):35177535.
- [38]. Yang W, Shaman J. SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant. *medRxiv*. 2021 Jan 1.
- [39]. Huy LD, Shih CL, Chang YM, Nguyen NT, Phuc PT, Ou TY, Huang CC. Comparison of COVID-19 Resilience Index and Its Associated Factors across 29 Countries during the Delta and Omicron Variant Periods. *Vaccines*. 2022 Jun 13;10(6):940.
- [40]. Gautret P, Hoang VT, Jimeno MT, Lagier JC, Rossi P, Fournier PE, Colson P, Raoult D. The severity of the first 207 infections with the SARS-CoV-2 Omicron BA. 2 variant, in Marseille, France, December 2021–February 2022. *Journal of medical virology*. 2022 Apr 1.
- [41]. Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Chuenkitmongkol S, Dung D, Hwang KP, Ortiz Ibarra J, Kiertiburanakul S, Kulkarni PS. Expert Review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. *Expert Review of Vaccines*. 2022 Sep 6(just-accepted).
- [42]. Sidhu JS, Dosch J. Brunei Darussalam in 2021: The Battle against COVID-19 and a Year of Short-Lived Optimism. *Southeast Asian Affairs*. 2022;2022(1):91-106.
- [43]. Colnago M, Benvenuto GA, Casaca W, Negri RG, Fernandes EG, Cuminato JA. Risk Factors Associated with Mortality in Hospitalized Patients with COVID-19 during the Omicron Wave in Brazil. *Bioengineering*. 2022 Oct 20;9(10):584.
- [44]. Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?. *The Lancet Respiratory Medicine*. 2021 Aug 1;9(8):e77.

How to Cite

Mishra P, Tiwari D, Chanchal DK and Pal V. Omicron: The Variant of Concern. *International Journal of Pharmaceutical Science and Medicine* 2023; 1(1): 6-14.